Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Controlled Substances Policy topic
No spam. Unsubscribe anytime.
House approves bill to allow FDA‑approved crystalline psilocybin despite lawmakers’ safety concerns
Summary
On Jan. 23, 2025 the House approved House Bill 1063 to permit lawful use of crystalline polymorph psilocybin approved by the U.S. Food and Drug Administration. Some members urged caution and stronger implementation guardrails, citing potential mental‑health risks and the need to define controlled treatment settings.
House Bill 1063, which concerns the lawful use of crystalline polymorph psilocybin that is approved by the United States Food and Drug Administration (FDA), was adopted by the House on third reading on Jan. 23, 2025.
The bill was presented for third reading by the majority leader. Representative de Graaf urged a no vote, warning that the state may be “2 to 3 years out” from implementation and that adopting statutory approval now without regulatory guardrails could be premature. “There is the potential for psychotic break,” de Graaf said during floor remarks expressing concern about the chemical’s risks and the state’s readiness to regulate its use.
Representative Armagost said she has heard testimony from veterans’ groups and other communities about potential benefits in controlled settings but said the statutory language must more clearly define what constitutes a “controlled environment” and stronger guardrails for implementation. “Defining what a controlled environment is is something that I think needs to be a much stronger guardrail,” Armagost said on the floor.
After floor discussion, the House voted to adopt House Bill 1063 on third reading and final passage. The recorded vote was 46 in favor, 16 opposed, 2 excused and 1 vacancy. Mister Schiebel opened and closed the voting machine and announced the tally.
Floor remarks focused on the balance between potential therapeutic benefits (including testimony reported from veterans’ conferences) and the need for robust regulation, especially given the chemical’s potency and the possible risks of improper use outside supervised settings. Members identified unanswered implementation questions — including program safeguards, definitions of treatment settings, and timelines for availability — but the House moved the bill forward.
The bill title read on the floor was: “House bill 1063 by Representatives Hartzook and Brown, also Senator Michael Cynginet, concerning the lawful use of crystalline polymorth psilocybin that is approved by the United States Food and Drug Administration.”
